MD20160138A2 - Combinaţie - Google Patents
CombinaţieInfo
- Publication number
- MD20160138A2 MD20160138A2 MDA20160138A MD20160138A MD20160138A2 MD 20160138 A2 MD20160138 A2 MD 20160138A2 MD A20160138 A MDA20160138 A MD A20160138A MD 20160138 A MD20160138 A MD 20160138A MD 20160138 A2 MD20160138 A2 MD 20160138A2
- Authority
- MD
- Moldova
- Prior art keywords
- skin diseases
- composition
- combination
- phosphoinositide
- autoantibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Invenţia se referă la o compoziţie farmaceutică, care cuprinde (a) un compus ce reprezintă un inhibitor al fosfoinozitid 3-kinazei delta, sau o sare acceptabilă farmaceutic şi/sau un solvat al acestuia şi (b) un corticosteroid, precum şi la utilizarea compoziţiei date pentru tratamentul bolilor de piele, în special al bolilor de piele imunobuloase mediate de autoanticorpi, îndeosebi al pemfigusului vulgar.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382192 | 2014-05-27 | ||
| EP14382400 | 2014-10-17 | ||
| EP14382401 | 2014-10-17 | ||
| PCT/EP2015/061312 WO2015181055A1 (en) | 2014-05-27 | 2015-05-21 | Combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD20160138A2 true MD20160138A2 (ro) | 2017-05-31 |
Family
ID=53269467
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160137A MD20160137A2 (ro) | 2014-05-27 | 2015-05-21 | Utilizare medicală |
| MDA20160138A MD20160138A2 (ro) | 2014-05-27 | 2015-05-21 | Combinaţie |
| MDA20160132A MD20160132A2 (ro) | 2014-05-27 | 2015-05-21 | Săruri de adiţie ale (S)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirolo[1,2-f][1,2,4]triazin-5-carbonitrilului |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160137A MD20160137A2 (ro) | 2014-05-27 | 2015-05-21 | Utilizare medicală |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160132A MD20160132A2 (ro) | 2014-05-27 | 2015-05-21 | Săruri de adiţie ale (S)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirolo[1,2-f][1,2,4]triazin-5-carbonitrilului |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20170189409A1 (ro) |
| EP (3) | EP3148585A1 (ro) |
| JP (3) | JP2017516799A (ro) |
| KR (3) | KR20170010369A (ro) |
| CN (3) | CN106414449A (ro) |
| AU (3) | AU2015266191A1 (ro) |
| BR (1) | BR112016024538A2 (ro) |
| CA (3) | CA2944611A1 (ro) |
| CL (2) | CL2016002970A1 (ro) |
| CR (3) | CR20160537A (ro) |
| EA (3) | EA201692437A1 (ro) |
| IL (3) | IL247073A0 (ro) |
| MA (3) | MA39828A (ro) |
| MD (3) | MD20160137A2 (ro) |
| MX (3) | MX2016014864A (ro) |
| PE (2) | PE20170145A1 (ro) |
| PH (3) | PH12016502256A1 (ro) |
| SG (3) | SG11201606763VA (ro) |
| TW (3) | TW201625260A (ro) |
| UY (3) | UY36151A (ro) |
| WO (3) | WO2015181055A1 (ro) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
| CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US10993947B2 (en) | 2016-05-18 | 2021-05-04 | Torqur | Treatment of skin lesions |
| GB201608797D0 (en) * | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
| CN107456454A (zh) * | 2016-06-06 | 2017-12-12 | 先声药业有限公司 | 一种预防或治疗炎性疾病的药物组合物 |
| WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| GB201708856D0 (en) * | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
| WO2019101853A1 (en) * | 2017-11-23 | 2019-05-31 | Piqur Therapeutics Ag | Treatment of skin disorders |
| WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| CN113440614A (zh) * | 2020-03-26 | 2021-09-28 | 长沙晶易医药科技有限公司 | 一种用于治疗类风湿性关节炎的组合物及其应用 |
| KR20230065591A (ko) * | 2021-11-05 | 2023-05-12 | 연세대학교 산학협력단 | 피부-특이적 T 세포(skin-specific T cell)의 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
| WO2023114369A2 (en) * | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of pi3k-delta inhibitors |
| TWI823476B (zh) * | 2022-07-15 | 2023-11-21 | 中化合成生技股份有限公司 | 托法替尼檸檬酸鹽的製備方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101123968A (zh) * | 2004-06-04 | 2008-02-13 | 艾科斯有限公司 | 肥大细胞病的治疗方法 |
| WO2007023186A1 (en) * | 2005-08-26 | 2007-03-01 | Laboratoires Serono S.A. | Pyrazine derivatives and use as pi3k inhibitors |
| JP2012521994A (ja) * | 2009-03-24 | 2012-09-20 | ギリアード カリストガ エルエルシー | ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法 |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
-
2015
- 2015-05-21 MD MDA20160137A patent/MD20160137A2/ro not_active Application Discontinuation
- 2015-05-21 CA CA2944611A patent/CA2944611A1/en not_active Abandoned
- 2015-05-21 US US15/313,722 patent/US20170189409A1/en not_active Abandoned
- 2015-05-21 MD MDA20160138A patent/MD20160138A2/ro not_active Application Discontinuation
- 2015-05-21 MX MX2016014864A patent/MX2016014864A/es unknown
- 2015-05-21 CR CR20160537A patent/CR20160537A/es unknown
- 2015-05-21 KR KR1020167033156A patent/KR20170010369A/ko unknown
- 2015-05-21 WO PCT/EP2015/061312 patent/WO2015181055A1/en active Application Filing
- 2015-05-21 US US15/313,737 patent/US20170151264A1/en not_active Abandoned
- 2015-05-21 SG SG11201606763VA patent/SG11201606763VA/en unknown
- 2015-05-21 KR KR1020167033149A patent/KR20170007760A/ko unknown
- 2015-05-21 CN CN201580028179.4A patent/CN106414449A/zh active Pending
- 2015-05-21 SG SG11201607950SA patent/SG11201607950SA/en unknown
- 2015-05-21 WO PCT/EP2015/061308 patent/WO2015181053A1/en active Application Filing
- 2015-05-21 EP EP15725295.8A patent/EP3148585A1/en not_active Withdrawn
- 2015-05-21 CA CA2941436A patent/CA2941436A1/en not_active Abandoned
- 2015-05-21 MA MA039828A patent/MA39828A/fr unknown
- 2015-05-21 AU AU2015266191A patent/AU2015266191A1/en not_active Abandoned
- 2015-05-21 JP JP2016569770A patent/JP2017516799A/ja active Pending
- 2015-05-21 CN CN201580028234.XA patent/CN106456777A/zh active Pending
- 2015-05-21 EP EP15726063.9A patent/EP3148586A1/en not_active Withdrawn
- 2015-05-21 EA EA201692437A patent/EA201692437A1/ru unknown
- 2015-05-21 EA EA201692435A patent/EA201692435A1/ru unknown
- 2015-05-21 CR CR20160536A patent/CR20160536A/es unknown
- 2015-05-21 PE PE2016002228A patent/PE20170145A1/es not_active Application Discontinuation
- 2015-05-21 CA CA2941429A patent/CA2941429A1/en not_active Abandoned
- 2015-05-21 AU AU2015266190A patent/AU2015266190A1/en not_active Abandoned
- 2015-05-21 MD MDA20160132A patent/MD20160132A2/ro not_active Application Discontinuation
- 2015-05-21 CN CN201580028312.6A patent/CN107074862A/zh active Pending
- 2015-05-21 BR BR112016024538A patent/BR112016024538A2/pt not_active Application Discontinuation
- 2015-05-21 MA MA039829A patent/MA39829A/fr unknown
- 2015-05-21 PE PE2016002230A patent/PE20170385A1/es not_active Application Discontinuation
- 2015-05-21 CR CR20160538A patent/CR20160538A/es unknown
- 2015-05-21 EP EP15725294.1A patent/EP3148999A1/en not_active Withdrawn
- 2015-05-21 KR KR1020167032089A patent/KR20170012236A/ko unknown
- 2015-05-21 MX MX2016014904A patent/MX2016014904A/es unknown
- 2015-05-21 MX MX2016014861A patent/MX2016014861A/es unknown
- 2015-05-21 MA MA039827A patent/MA39827A/fr unknown
- 2015-05-21 JP JP2016569769A patent/JP2017516798A/ja active Pending
- 2015-05-21 AU AU2015266193A patent/AU2015266193A1/en not_active Abandoned
- 2015-05-21 WO PCT/EP2015/061307 patent/WO2015181052A1/en active Application Filing
- 2015-05-21 US US15/313,762 patent/US20170158699A1/en not_active Abandoned
- 2015-05-21 JP JP2016569768A patent/JP2017516797A/ja active Pending
- 2015-05-21 EA EA201692436A patent/EA201692436A1/ru unknown
- 2015-05-21 SG SG11201606762PA patent/SG11201606762PA/en unknown
- 2015-05-25 TW TW104116634A patent/TW201625260A/zh unknown
- 2015-05-25 TW TW104116629A patent/TW201625258A/zh unknown
- 2015-05-25 TW TW104116630A patent/TW201625259A/zh unknown
- 2015-06-03 UY UY0001036151A patent/UY36151A/es not_active Application Discontinuation
- 2015-06-03 UY UY0001036153A patent/UY36153A/es not_active Application Discontinuation
- 2015-06-03 UY UY0001036152A patent/UY36152A/es not_active Application Discontinuation
-
2016
- 2016-08-02 IL IL247073A patent/IL247073A0/en unknown
- 2016-08-02 IL IL247072A patent/IL247072A0/en unknown
- 2016-09-19 IL IL247901A patent/IL247901A0/en unknown
- 2016-11-11 PH PH12016502256A patent/PH12016502256A1/en unknown
- 2016-11-11 PH PH12016502252A patent/PH12016502252A1/en unknown
- 2016-11-11 PH PH12016502255A patent/PH12016502255A1/en unknown
- 2016-11-21 CL CL2016002970A patent/CL2016002970A1/es unknown
- 2016-11-21 CL CL2016002971A patent/CL2016002971A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20160138A2 (ro) | Combinaţie | |
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
| EP3621973A4 (en) | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THEIR USE | |
| EP3490603A4 (en) | MASP-3 INHIBITION COMPOSITIONS AND METHODS FOR THE TREATMENT OF MISCELLANEOUS DISEASES AND CONDITIONS | |
| EP3790867A4 (en) | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | |
| MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
| EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
| EP3600286A4 (en) | COMPOUNDS AND METHODS FOR TREATMENT OF PARASITIC DISEASES | |
| EP3294314A4 (en) | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES | |
| WO2016004807A3 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| EP3261671A4 (en) | Combination therapy for treatment of coronary artery disease | |
| EP3197474A4 (en) | Inhibitors of nf kappa-b activity for treatment of diseases and disorders | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| EP3322435A4 (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| EP3560505A4 (en) | INNOVATIVE THERAPEUTICS FOR PRIONOID DISEASES | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| EP3340985A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF HYPOXIC-INFLAMMATORY DISEASES | |
| GB201720101D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3389649A4 (en) | CONNECTION FOR THE TREATMENT AND / OR PREVENTION OF PARASITISED DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Abandonment or withdrawal of application (patent for invention) |